Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial

Anne Boerekamps, A De Weggheleire, GE van den Berk, FN Lauw, MAA Claassen, D Posthouwer, WF Bierman, Sebastiaan Hullegie, Stephanie Popping, David van de Vijver, ASM Dofferhoff, GJ Kootstra, EM Leyten, J Hollander, ME van Kasteren, R Soetekouw, HSM Ammerlaan, J Schinkel, E Florence, JE ArendsBart Rijnders

Research output: Contribution to journalArticleAcademicpeer-review

25 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)269-277
Number of pages9
JournalLancet Gastroenterology & Hepatology
Volume4
Issue number4
DOIs
Publication statusPublished - 2019

Cite this